Complex assessment of inhacort effectiveness in bronchial asthma
Kakhnovskiĭ, I.M.; Marinin, V.F.; Arkhipova, S.V.; Sorokina, L.A.; Makhnach, G.K.
Terapevticheskii Arkhiv 70(9): 73-76
1998
ISSN/ISBN: 0040-3660 PMID: 9821234 Document Number: 487483
To investigate efficiency of inhacort in long-term (6 months to 2 years) treatment of bronchial asthma (BA). 67 inpatients and 65 outpatients with moderate BA were divided into two groups. 96 patients of group 1 had received standard combined treatment without glucocorticosteroids (GCS), 36 patients of group 2 had received GCS. Inpatients were given inhacort in a dose 1000 micrograms/day, outpatients took inhacort in a daily dose 500 micrograms/day. The examination scheme included assessment of external respiration function (ERF), blood hydrocortisone, sputum rheology and diagnosis of candidosis. Inhacort treatment has reduced frequency of asphyxia attacks 2.5-fold 30 and 25% of the patients stopped taking sympathomimetics and GCS, respectively. None of the patients had asphyxia as a status. ERF, sputum viscosity improved, hydrocortisone secretion was unchanged. Only 3.8% of the patients developed oral candidosis. Inhacort in a dose 1 mg controls BA. 73% of the patients treated outpatiently had no need in hospitalization.